文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

嵌合抗原受体T细胞疗法简述。

A brief review concerning Chimeric Antigen Receptors T cell therapy.

作者信息

Li Ling-Lin, Yuan Hong-Ling, Yang Yu-Qiong, Wang Lin, Zou Ren-Chao

机构信息

Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, Yunnan, China.

Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.

出版信息

J Cancer. 2020 Jul 11;11(18):5424-5431. doi: 10.7150/jca.46308. eCollection 2020.


DOI:10.7150/jca.46308
PMID:32742489
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7391193/
Abstract

The understanding concerning the function of immune system in cancer has achieved considerable advance with time passes by. Manipulating genetically engineered immune cells were investigated as a novel strategy for treating cancer. Chimeric antigen receptors (CARs) are recombinant protein molecules by merging the exquisite targeting the potent cytotoxicity of T cells and specificity of monoclonal antibodies and, which could trigger serial cascades of signal transduction and thereby activate T cells to directly destroy the tumor cells. Manufacturing CAR-modified T lymphocytes were successfully implemented in treating cancer derived from they could specifically retarget tumor-associated antigens, causing effective elimination of tumor cells, which spurred the optimization and development of new CAR-T cell technology. The advancement of synthetic biology methodologies of cell therapy in CAR-T would ultimately provide us with a much safer, reliable and efficient modality to against cancer. This review primarily described the emergence, development and application of cell therapy in CAR-T, then discuss the side effects and the potential factors of tumor reccurrence caused by CAR-T cell therapy, in addition to the corresponding countermeasure concerning complications.

摘要

随着时间的推移,关于免疫系统在癌症中的作用的认识取得了长足的进展。对基因工程改造的免疫细胞进行操控作为一种治疗癌症的新策略受到了研究。嵌合抗原受体(CARs)是通过将T细胞强大的细胞毒性的精准靶向与单克隆抗体的特异性相结合而形成的重组蛋白分子,其能够触发一系列信号转导级联反应,从而激活T细胞直接摧毁肿瘤细胞。制造CAR修饰的T淋巴细胞已成功应用于癌症治疗,因为它们可以特异性地重新靶向肿瘤相关抗原,有效清除肿瘤细胞,这推动了新型CAR-T细胞技术的优化和发展。CAR-T细胞疗法中细胞治疗的合成生物学方法的进步最终将为我们提供一种更安全、可靠和有效的抗癌方式。本综述主要描述了CAR-T细胞疗法中细胞治疗的出现、发展和应用,然后讨论了CAR-T细胞疗法引起的副作用和肿瘤复发的潜在因素,以及针对并发症的相应对策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3e6/7391193/5756107e26e0/jcav11p5424g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3e6/7391193/3e041745db59/jcav11p5424g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3e6/7391193/5756107e26e0/jcav11p5424g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3e6/7391193/3e041745db59/jcav11p5424g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3e6/7391193/5756107e26e0/jcav11p5424g002.jpg

相似文献

[1]
A brief review concerning Chimeric Antigen Receptors T cell therapy.

J Cancer. 2020-7-11

[2]
T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.

Biochim Biophys Acta. 2014-1

[3]
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.

Hepatobiliary Pancreat Dis Int. 2018-5-24

[4]
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity.

J Virol. 2015-7

[5]
Engineering Chimeric Antigen Receptors.

Acta Naturae. 2017

[6]
Chimeric Antigen Receptor beyond CAR-T Cells.

Cancers (Basel). 2021-1-22

[7]
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.

Cell Commun Signal. 2020-8-25

[8]
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.

Mol Ther. 2017-7-20

[9]
CAR T cells: Building on the CD19 paradigm.

Eur J Immunol. 2021-9

[10]
Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.

Cancer Immunol Immunother. 2019-8-14

引用本文的文献

[1]
Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications.

Heliyon. 2024-3-16

[2]
Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines.

Vaccines (Basel). 2021-10-25

[3]
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.

Stem Cell Rev Rep. 2021-12

本文引用的文献

[1]
Replacing CAR-T cell resistance with persistence by changing a single residue.

J Clin Invest. 2020-6-1

[2]
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.

Cell. 2019-8-22

[3]
Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.

Clin Cancer Res. 2019-5-20

[4]
Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells.

Adv Mater. 2019-3-27

[5]
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy.

Trends Cell Biol. 2019-2-11

[6]
Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety.

Int J Mol Sci. 2018-11-3

[7]
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.

Onco Targets Ther. 2018-10-4

[8]
CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.

Front Immunol. 2018-7-27

[9]
Innate Immunity of Neonates and Infants.

Front Immunol. 2018-7-30

[10]
Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells.

Front Immunol. 2018-6-29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索